What is Claimed:

1. Use of at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of reducing the likelihood that an injured patient or subject at risk of an inflammatory syndrome will produce one or more of sepsis, septic shock, an acute inflammatory syndrome (whether iatrogenic or not) or acute respiratory distress syndrome, wherein the method comprises administering the medicament alone or in combination with at least one antibiotic to the patient or subject.

2. The use according to claim 1, wherein said medicament is combined with or administered with at least one antibiotic.

3. Use of at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of treating an injured or burned patient or subject to improve wound healing of injured and/or burned tissue and/or to inhibit, ameliorate or reduce the likelihood of one or more of sepsis, septic shock, acute inflammatory syndrome, including inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS) in said patient or subject, wherein the method comprises administering the medicament in combination with at least one antibiotic to the patient or subject.

4. Use of at least one PLA2 inhibitor and/or metalloprotease inhibitor in the manufacture of a medicament for use in a method of treating a patient or subject with sepsis, including early sepsis, wherein the method comprises administering the medicament in combination with at least one antibiotic to the patient or subject.

5. Use of at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor in the manufacture of a medicament for inhibiting or reducing the likelihood of a COVID-19/cytokine release syndrome in a patient at risk of same.

6. Use of at least one PLA2 inhibitor in the manufacture of a medicament for treating neo-natal acute respiratory distress syndrome (neo-natal ARDS), including meconium aspiration syndrome.

7. Use according to claim 6, wherein said neo-natal ARDS is meconium aspiration syndrome (MAS).

8. A pharmaceutical composition for use in a method of treating a patient at risk for or afflicted with one or more of sepsis, septic shock, acute inflammatory syndrome, including inflammatory response syndrome (SIRS) and/or acute respiratory distress syndrome (ARDS), comprising at least one PLA2 inhibitor and/or at least one metalloprotease inhibitor, wherein the composition further comprises at least one antibiotic or is administered in combination with at least one antibiotic.

9. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one PLA2 inhibitor.

10. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one metalloprotease inhibitor.

11. The use or the pharmaceutical composition according to any one of claims 1-5 and 8, wherein said medicament or pharmaceutical composition comprises at least one PLA2 inhibitor and at least one metalloprotease inhibitor

12. The use or the pharmaceutical composition according to any one of claims 1-11, wherein said PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716- as a racemic mixture or enantiomer thereof, AZD Compound 4, LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl}oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof.

13. The useor the pharmaceutical composition according to any one of claims 1-5 and 8-12, wherein said metalloprotease inhibitor is prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, cefixime and doxycycline, a pharmaceutically acceptable salt thereof or a mixture thereof.

14. The use use or the pharmaceutical composition according to any one of claims 1-4 and 8-13, wherein said antibiotic is selected from the group consisting of a penam, a carboxylpenicillin, a cephalosporin, a monobactam, a carbapenem, a fluoroqunoline, a macrolide or a mixture thereof.